Receipt of Finished Nutraceutical Products
Sydney, June 15, 2021 AEST (ABN Newswire) - Further to Azure Health Technology Limited's (
NSX:VTL) announcement on 16 March 2021 that the first manufacturing run for our finished nutraceutical products has been completed, Azure Health Technology Limited trading as VGI Health Technology (the Company or VTL) is pleased to announce that we have now received these products in our warehouse in Florida, USA and they are ready for sale in the US.
VTL's CEO and Managing Director, Dr Glenn Tong, said that this is a major milestone for VTL as we are now commencing the launch of both our patented nutraceutical products, NE1-Elite(R) for reduction of Delayed Onsent Muscle Soreness (DOMS) and NE1-Heart(R) for maintenance of heart health in the US.
About VGI Health Technology Limited
VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.
| ||
|
